Login to Your Account



Safety Issues Force IntraBiotics To Halt Iseganan VAP Program

By Karen Pihl-Carey


Thursday, June 24, 2004
Just as researchers geared up to start a second pivotal trial of iseganan in ventilator-associated pneumonia (VAP), the floor fell from beneath IntraBiotics Pharmaceuticals Inc. Wednesday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription